DoH Policies screened during the period 1 July – 30 September
Date published: 01 December 2023
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
NICE Technology Appraisal TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (PDF 511KB)